Portfolio company
Arima Genomics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops 3D genomic sequencing kits and clinical diagnostic tests for researchers and pharmaceutical companies to identify cancer-driving genetic alterations.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ultima Genomics
This company develops and manufactures high-throughput DNA sequencing platforms for researchers and clinicians performing population-scale genomic analysis.
CytoTerra
This company develops next-generation sequencing assays to detect chromosomal abnormalities for clinical researchers and healthcare providers specialising in oncology and genetic diseases.
JUMPCODE Genomics
This company develops CRISPR-based reagent kits that remove unwanted genetic sequences from sequencing libraries for researchers in oncology, infectious disease and basic research.
BioSkryb
This company develops genomic amplification and sequencing systems for researchers and clinicians to analyse DNA and RNA from single cells.
Univ8 Genomics
This company provides next-generation sequencing kits and analysis software to clinical laboratories for the diagnosis and monitoring of cancers including leukaemia and lymphoma.
GeneCentric
This company develops gene expression-based liquid biopsy platforms and biomarkers to help pharmaceutical and diagnostic firms identify cancer treatment responders.
Avant Genomics
The company develops an automated platform for liquid biopsy sample preparation to assist clinical laboratories in cancer detection and monitoring.
Phase Genomics
Phase Genomics develops proximity ligation kits and computational tools for genome assembly and metagenomic analysis used by researchers in oncology, agriculture and microbiology.
